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Abstract
For several decades, testosterone and its synthetic derivatives have been used with anabolic and androgenic
purposes. These substances were first restricted to professional bodybuilders, but become more and more popular
among recreational athletes. Up to date, 3,000,000 anabolic-androgenic steroids (AAS) users have been reported in
the United States with an increasing prevalence, making AAS consumption a major public health growing concern.
Infertility is defined by the WHO as the failure to achieve a clinical pregnancy after 12 months or more of regular
unprotected sexual intercourse and a male factor is present in up to 50 % of all infertile couples. Several conditions
may be related to male infertility.
Substance abuse, including AAS, is commonly associated to transient or persistent impairment on male
reproductive function, through different pathways. Herein, a brief overview on AAS is offered. Steroids biochemistry,
patterns of use, physiological and clinical issues are enlightened. A further review about fertility outcomes among
male AAS abusers is also presented, including the classic reports on transient anabolic steroid-induced
hypogonadism (ASIH), and the more recent experimental reports on structural and genetic sperm damage.
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Resume
Depuis plusieurs décennies, la testostérone et ses dérivés synthétiques ont été utilisés à des fins anaboliques et
androgéniques. Initialement réservées aux culturistes professionnels, ces substances ont été progressivement
utilisées par les athlètes et les pratiquants de la musculation.
Actuellement, pas moins de 3 millions d’utilisateurs de stéroïdes anabolisants ont été signalés aux États-Unis, et la
prévalence croissante de cette utilisation fait de ce phénomène un sujet de préoccupation majeur.
L’infertilité est définie comme l’incapacité à obtenir une grossesse réussie après 12 mois ou plus de rapports sexuels
réguliers non protégés, le facteur masculin étant impliqué dans 30 à 50 % des cas parmi tous les couples infertiles.
L’abus de substances, y compris les anabolisants, est souvent associé à une altération transitoire ou persistante sur
la fonction reproductive mâle par différentes voies.
Un aperçu des produits anabolisants couramment utilisés ainsi que leurs modes d'utilisation et mécanismes d’action
sont présentés. Les implications sur la fertilité sont détaillées. Outre l’inhibition axiale transitoire, les dommages
structurels et génétiques des spermatozoïdes, connus à ce jour, sont décrits. Enfin, la spécificité et les modalités de
la prise en charge thérapeutique de cette catégorie de patients infertiles sont évoquées.
Mots cles: Anabolisants androgènes stéroïdiens, Infertilité masculine, Hypogonadisme
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Introduction
For several decades, testosterone and its synthetic de-
rivatives have been used with anabolic and androgenic
purposes. Initially, these substances were restricted to
professional bodybuilders, becoming gradually more
popular among recreational power athletes.
Up to date, 3,000,000 Anabolic-Androgenic Steroids
(AAS) users have been reported in the United States
[1, 2], and considering its increasing prevalence, AAS
consumption has become an issue of major concern.
When combined with a proper diet and an intense
training program, anabolic steroids are able to increase
strength and muscle mass in some people. They have
many side effects which can be permanent or potentially
fatal. Most side effects are mild and reversible like
the alteration of the male reproductive system, discussed
in this article.
The abuse of anabolic steroids, is often associated with
transient or persistent alterations of male reproductive
function by different routes.
Background
Epidemiology
Since testosterone isolation and characterization in 1935,
many derivatives have been synthetized, which properties
differ from those of testosterone. These derivatives are
called anabolic-androgenic steroids (AAS), or more com-
monly, anabolic steroids. Initially, these substances were
restrictly used by professional athletes and bodybuilders.
Nowadays, non-professional and recreational use become
more and more popular.
Recent international studies reported an overall lifetime
prevalence of AAS use for men of 3–4 % [3] and of 1.6 %
for women [4]. AAS use among male gym attendees
is estimated to be as high as 15–25 %, depending on
the country and with an increasing prevalence [5–7].
Actually, 3,000,000 AAS users have been reported in
the United States [1]. By contrast, AAS use is rare in
Eastern Asia [2]. Nevertherless, rates of AAS use are also
high in Scandinavia, Brazil, British Commonwealth coun-
tries, and in Europe [2]. This increasing prevalence of
AAS consumption in become a major public health issue
in these countries.
Perry et al. studied the steroid regimen (called “cycle”)
of 207 AAS consumers. The authors reported an average
consumption of 3.1 product per person and per cycle dur-
ing the 5 to 10 weeks cycles, with doses often being 5 to
29 times the physiological replacement doses [8]. Depend-
ence to AAS was reported by 33 % of respondents. These
results suggest that the use of AAS among weightlifters
and bodybuilders, usually involving different types of
steroids and several additional dietary agents, can lead to
adverse reactions, polypharmacy, high doses consumption
and addiction for at least 1/3 of them.
Law
According to Article L232-9 of the Code of Sport in
France [9], it is forbidden for any athlete to hold or
use, without duly justified medical reason, dopants or
restricted products at sporting competitions or events.
Concerning Prohibition of this practice, the World Anti-
Doping Code [10] has proven to be a very powerful and
effective tool in the harmonization of anti-doping efforts
worldwide, but not enough to fight against this illegal
phenomenon.
Physiopathology
Testosterone is the most important androgen in the hu-
man body. Effects of androgens are most evident during
puberty, when they induce deep physiological changes in
the male body: development of secondary male charac-
teristics, hair growth pattern, sebaceous gland activity,
sperm maturation and libido. Testosterone has several
possible metabolic fates [11].
First, it binds to the androgen receptor (AR) in target
tissues to exert its effects. Second, it is reduced to 5 α-
dihydrotestosterone (5DHT), which also acts on the AR.
Following a different path, testosterone may be aroma-
tized to estradiol to exert estrogenic effects, typically
water retention, breast tissue growth and an increase in
body fat deposition.
Anabolism and androgenism
Anabolism is defined as any state in which nitrogen is
differentially retained in lean body mass through the
stimulation of protein synthesis and/or a reduction in
protein breakdown [12]. It includes growth promotion,
protein and collagen synthesis and an increase in muscle
size and bone metabolism.
Androgenism is defined as physiological changes in
the male body, including the onset of secondary male
characteristics, hair growth pattern, sebaceous gland
activity, maturation of sperm and libido.
Characteristically, more anabolic steroids present weaker
AR bindings, and more androgenic steroids strongly bind
the AR, exerting a more potent effect.
Anabolic steroids: beyond testosterone
Structural changes have been made to the testosterone
molecule in order to maximize the anabolic effects and
minimize the androgenic ones. However, all AASs are
virilizing if administered for long time enough, at high
enough dosages [13]. Traditionally, AASs are classified
into two categories according to the route of administration
and their carrier solvent [2, 14, 15]:
 Oral AAS or 17 α-esterified steroids:
17 α-alkylated AAS group originate from the
substitution of the 17 αhydrogen on the steroid
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nucleus for a methyl or ethyl group. Alkyl
substitution prevents deactivation of the steroid by
hepatic first-pass metabolism (necessitating hepatic
monitoring), which promotes oral activity. They
usually have short half-lives, making daily doses
necessary to maintain appropriate blood levels. This
class includes the very common stanozolol and
oxandrolone, as well as methyltestosterone and others.
 Parenteral AAS or 17 β-esterified steroids:
Usually, the 17 β-hydroxyl group is oesterified with
an acid moiety to prevent rapid release from the oily
vehicle. Roughly, the longer the chain of the acid
moiety is, the more slowly the preparation is released
into the blood stream. Once in the circulation,
hydrolysis rapidly occurs yielding the active
compound. They usually have a longer half-life and a
slower absorption rate, bringing much less hepatic
stress than the orally taken steroids. Pain at injection
sites is common, because of the oily base.
There are four basic active compounds:
1. testosterone, bound to esters such as undecanoate,
cypionate, propionate and others;
2. 19-nortestosterone (or nandrolone), also bound to
different esters. Nandrolone is extremely popular,
owing to its high anabolic: androgenic ratio. In
contrast to testosterone, nandrolone is converted
to a less potent metabolite after 5 α-reduction.
This, in addition to nandrolone’s lesser affinity to
AR, explains the higher myotrophic: androgenic ratio;
3. boldenone, bound to ester undecylenate;
4. trenbolone, bound to ester acetate.
Anabolic-androgenic steroids may also be classified
according to their main effects as follows [2, 14, 15]:
 The “Testosterone-like” effect: The testosterone-like
effect is very potent, and allows great muscle
strength gains. These AASs usually show an
anabolic/androgenic ratio close to 1:1, similar to
testosterone itself. The high aromatization rates
are also comparable with those of testosterone.
They include all testosterone esters, methyltestosterone
and others.
 The “Dihydrotestosterone (DHT)-like” effect: The
DHT-like effect is potent but highly androgenic. As
these AASs resemble a 5DHT molecule, they cannot
be aromatized to estrogen and they also have a low
water and salt retention. These AASs include
stanozolol and oxandrolone.
 The “Nandrolone-like” effect: The nandrolone-like
effect is the least potent of all, with the highest
anabolic/androgenic ratio. The AASs in this group
have some progesterone-like activity, inhibiting
the hypothalamic axis. These AASs are the most
frequently used drugs in the clinical setting, when
anabolic effects are desired (they reverse catabolic
states, such as AIDS-associated cachexia, severe
burns, and chronic obstructive pulmonary disease).
They include the nandrolone esters and trembolone.
Modes of use
Different oral and injectable compounds are generally
combined (‘stacked’), creating large dose regimens, usu-
ally self-administered during 4–12 weeks long-lasting
periods (‘cycles’) [16]. ‘Stacking’ is based on the idea that
smaller dosages of multiple drugs might reduce the chance
of complications than larger dosages of a single drug. This
may also facilitate the administration of multiple AASs
(necessary to achieve supraphysiological doses) for longer
periods, and so minimizing the plateauing effect.
The aim of ‘stacking’ is to rationally combine different
characteristics, avoiding overlap of benefits or side ef-
fects. ‘Mass-building stacks’ consist of the combination
of testosterone and nandrolone (or similar drugs), used
to maximize muscular and strength gains. ‘Cutting
stacks’ consist of combinations containing potent andro-
gens, which are preferred for dieting and body definition,
because of their lack of estrogenic activity (less water,
salt and fat retention). Heavy users may combine a
‘mass-building cycle’, then ‘cutting cycle’, to finish by a
‘post-cycle therapy’ including anti-estrogens or human
Chorionic Gonadotropin (hCG), to try to restart andro-
gen production by the testicles. The Table 1 recapitulates
the different products used, their commercial name,
their prices and active agent.
Drugs used by AAS consumers are not confined to
anabolic steroids. Up to 90 % of AAS users have a palate
for polypharmacy, taking a mix of muscle-shaping drugs,
in addition to stacking different brands of steroids [6].
These “steroid-accessory” drugs are used for a variety
of reasons and can be grouped according to their desired
effect (Table 2). Some of these accessory drugs are po-
tentially more dangerous than AAS; the unsupervised
use of insulin, diuretics, and thyroxin can precipitate a
number of medical emergencies [17].
Physiological and clinical effects
The physiological direct effects of testosterone and AASs
(AR-mediated) are well known. They include increases
in renal erythropoietin stimulated hæmatopoiesis, lipoly-
sis, protein synthesis, sebaceous secretion, hair growth
and libido [13].
Concerning the muscle fiber hypertrophy, a study
showed that increases in muscle volume in healthy eugo-
nadal men treated with graded doses of testosterone are
associated with concentration-dependent increases in
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Table 1 Common oral and injection steroids available through the Internet
Type of product Administration
mode
Trade name Composition Active agent (Formula)
Anabolic Androgenic
Steroids (AAS)
Injection Boldenone 300 Boldenone Undeclynate Boldenone (C19H26O2)
Masteron 100 Drostanolone propionate Drostanolone (C23H36O3)
Winstrol 50 mg Stanozolol Stanozolol (C21H32N2O)
Trenbolone A100 Trenbolone Acetate Tremblone (C18H22O2)
Trenbolone E200 Trenbolone Enanthate
Tri-Trenbo Mixture of trenbolones: Trenbolone Enanthate
Trenbolone Acetate Trenbolone Hexahydro-
benzylcarbonate




Deca Rapide Nandrolone Phenypropionate
Deca durabolin 300 Nandrolone decanoate




Testosterone P100 Testosterone phenypropionate
Testosterone C250 Testosterone Cypionate
Testosterone E300 Testosterone Enanthate
PharmaMix-1 Mixture of: Testosterone Cypionate Boldenone
Undecylenate Testosterone Phenylpropionate
-
PharmaMix-2 Mixture of: Trenbolone Acetate Drostanolone
Propionate Testosterone Phenylpropionate
-
PharmaMix-3 Mixture of: Trenbolone Enanthate Nandrolone
Decanoate Testosterone Enanthate
-
Primobolan 100 Metenolone enanthate Metenolone (C27H42O3)
Oral Anavar 10 mg Oxandrolone Oxandrolone (C27H42O3)
Dianabol 10 mg Methandienone Methandienone (C20H28O2)
Winstrol tabs 10 mg Stanozolol Stanozolol (C21H32N2O)
Turanabol 10 mg Turanabol Turanabol (C20H27ClO2)
Anapolon 50 mg Oxymetholone Oxymetholone (C21H32O3)
Burners Clenbuterol – Meditech Clenbuterol hydrochlorid Clenbuterol (C1H18Cl2N2O)
T3 Cytomel T3 cytomel Cytomel (C15H11I3NaO4)
Triiodothyronine (C15H12I3NO4)
Post-cycle therapy Clomid 50 mg Clomifene citrate Clomifene (C26H28ClNO)
Nolvadex 20 mg Tamoxifen citrate Tamoxifen (C26H29NO)
Proviranos 50 mg Mesterolone Mesterolone (C20H32O2)
Proviron 25 mg Mesterolone
Anastrozolos 1 mg Anastrozol Anastrozol (C17H19N5)
Injection HCG 5000 UI Pregnyl Polypeptide
HCG 1500 UI Pregnyl
Other substances IGF1 Lr3 - Getropin Insulin-like Growth Factor 1
HGH HGH 100 UI - Getropin Getropin (C990H153N262O300S7)
Eporex 300 (EPO) Erythropoietin Erythropoietin (C809H1301N229O240S5)
Side Effects
Medications
Oral Finasteride - Prostacare Finasteride Finasteride (C23H36N2O2)
Viagra Sildenafil citrate Sildenafil (C22H30N6O4S)
Cialis Tadalafil Tadalafil (C22H19N3O4)
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cross-sectional areas of both type I and type II muscle fi-
bers and myonuclear number [18].
However, the indirect effects should also be considered.
These include antiglucocorticoid effects, which are medi-
ated by testosterone occupation of cortisol receptors
(which have a remarkable affinity with testosterone) and
create an anti-catabolic effect [19].
Side effects
Their incidence is unclear, as the denominator of AAS
use is not clear. Acne, alopecia and Lower Urinary Tract
Symptoms (LUTS) attributable to prostate enlargement
are usually related to the strong androgenic 5DHT-effect.
Erectile dysfunction and libido loss may also occur, espe-
cially after discontinuation, when endogenous testosterone
levels are usually low [13].
A sustained increase in testosterone levels during
‘cycles’ leads to higher aromatization rates of testosterone,
which accounts for the gynecomastia typically found in
steroid users. Hepatic effects are most often related to oral
alkylated agents. They include the uncommon hepatic
peliosis, cholestatic jaundice and hepatic neoplasms, such
as focal nodular hyperplasia, which are all closely related
to dose and duration of usage [20].
Hepatocellular carcinoma and Wilm’s tumour are serious
and rare side effects that are always related to long-term
and heavy use. Interestingly, there are no recent reports
linking AASs to prostate cancer or significant increases in
PSA levels. The most severe consequences of long-term
AAS use are associated with the cardiovascular system.
Hypertension, arrhythmia, erythrocytosis and ventricular
dysfunctions have been reported. Mortality risk among
chronic users is estimated to be 4.6 times higher than
among non-users. Cases of renal failure secondary to
rhabdomyolysis and diffuse membranoproliferative glomer-
ulonephritis in heavy users have been reported. Aggressive
behaviour, depression, mood swings, altered libido, eu-
phoria and even psychosis are some of the psychiatric
patterns related to AAS [21].
Overpharmacy may increase the risk of violent crimin-
ality. Withdrawal syndrome and dependency were also
described, and the likelihood of psychiatric effects is
greater where there is previous psychiatric history, or
alcohol or drug abuse [22].
During AAS withdrawal, depressive episodes were re-
ported among untreated AAS users in addition to the sig-
nificant decrease on the IIEF sexual desire subscale [23].
Impact on fertility
Androgen and spermatogenesis
Androgens play a crucial role in the development of male
reproductive organs such as the epididymis, vas deferens,
seminal vesicles, prostate and penis. In addition, andro-
gens are necessary for puberty, male fertility and male sex-
ual function. High levels of intratesticular testosterone
secreted by Leydig cells, are required for spermatogenesis.
The AR is in all male reproductive organs and can be
stimulated either by testosterone or its potential me-
tabolite: dihydrotestosterone [24].
Classic reversible AAS-induced hypogonadotropic
hypogonadism
Exogenous administration of testosterone synthesis
derivatives induces negative feedback on the hypothalamic-
pituitary axis and therefore inhibiting the secretion of both
FSH and LH. Infertility after AAS abuse commonly pre-
sents as oligozoospermia or azoospermia, associated with
abnormalities in sperm motility and morphology [25].
Innovative experimental AAS-induced findings
Histopathology
Experiments in animal models mainly report AAS-
induced Leydig cell alterations, but cellular morphology
anomalies have also been reported [26]. Nethertheless,
specific end-stage spermatogenesis impairment, with a
lack of advanced forms of spermatids, has been described
[27]. After AAS discontinuation, Leydig cells tend to pro-
liferate but remain below the regular counts, even after
longer periods [28].
Apoptosis
Apoptosis has been reported to play an important role
in the regulation of germ cell populations in the adult
testis. Recently, the correlation between apoptosis and
high AAS doses and exercises has been experimentally
Table 2 Accessory Drugs and Dietary Supplements [17]
Drug/Supplement Reason for use
Ephedrine Stimulant, fat loss
Clenbutarol Stimulant, fat loss
Amphetamine Stimulant, fat loss
Thyroxine Thyroid hormone, fat loss
Growth hormone Anabolic, increase muscle mass and
strength
Insulin Anabolic, increase muscle mass






Gamma-hydroxybutyrate Sedative, aids sleep/releases growth
hormone
Opioids Pain relief
Androstenedione Over-the-counter testosterone precursor
Creatine Over-the-counter ergogenic supplement
Dihydroepiandosterone Over-the-counter steroid precursor
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assessed in animal models. Shokri et al. report a signifi-
cant increase in the rate of apoptosis of spermatogenic
cells after nandrolone administration, an increase clearly
amplified by physical exercise [29].
Aneuploidies and ultrastructural changes in
spermatozoa
The innovative use of both transmission electron mi-
croscopy and fluorescence in situ hybridization (FISH)
has recently been reported in an AAS user sperm sample,
searching for genetic and ultrastructural consequences of
steroid abuse. Immaturity, necrosis and apoptosis were
assessed, and a high percentage of structurally normal
spermatozoa were found, which showed the absence of a
correlation between AAS and ultrastructural sperm
changes. In contrast to these findings, FISH sperm
analysis revealed XY and chromosomes 1 and 9 disomies,
suggesting anomalies in the meiotic process and genetic
damage among AAS users [30].
Sperm parameters
The use of a combination of hCG and steroids is a
common practice among AAS users. The aim is to
avoid the impact of the negative feedback on LH after
long term AAS administration, which may lead to a per-
sistent state of hypogonadism and poor sperm quality. In a
study of colts, the long-term effects of the anabolic steroid
19-norandrostenololylaurate on sperm characteristics were
studied in three experiments [31]. It was concluded that
the adverse effects of corticosteroids on semen characteris-
tics were reversible, at least in the treated groups at the age
of 7–25 months. In another study on sperm parameters, it
was concluded that according to the duration of use of ana-
bolic steroids and the period since the last drug administra-
tion prior to the survey, the percentages of motile sperm
and whose form is normal were significantly reduced
among bodybuilders compared to healthy volunteers [32].
These results suggest that, even after prolonged use of ex-
tremely high doses of anabolic steroids, sperm production
can return to normal rates for bodybuilders who stopped
the consumption of anabolic steroids over 4 months ago.
Treatment modalities
The infertility treatment with testosterone does not im-
prove spermatogenesis; the administered exogenous tes-
tosterone and its metabolite, estrogen, suppresses the
production of Gonadotropin-releasing hormone (GnRH)
by the hypothalamus and the production of luteinizing
hormone (LH) by the pituitary gland, and therefore the
production of testicular testosterone.
Reversible Anabolic-Steroid-induced hypogonadism (ASIH)
According to most reports, the quality of sperm tends to
normalize spontaneously within 4–12 months after
cessation of anabolic steroid abuse [32]. However, the
negative effect on sperm quality may persist for long pe-
riods. Simply stopping the use of ASA may lead to the
resumption of fertility in a certain proportion of male
users [33, 34]. Patients may also be treated by induction
of spermatogenesis with gonadotropins or gonadoliberin
analogues, including hCG IM injections, human meno-
pausal gonadotropin (hMG) or even recombinant FSH.
The use of hCG alone or in combination with hMG was
reported as an effective treatment for this group of patients
[35]. The restoration of fertility has been reported, even in
situations of persistent azoospermia up to 5 years after the
AAS stop [32]. Several different regimens are described in-
cluding testosterone replacement therapy (TRT), Selective
Estrogen Receptor Modulator (SERM) such as clomiphene
citrate and tamoxifen [36]. For resistant cases, injections of
human Chorionic Gonadotropin (hCG) can be used in as-
sociation with SERM treatment [36].
Withdrawal treatment
Stopping the use of large doses of anabolic steroids in
the long term can lead to the development of withdrawal
symptoms. They include: mood disorders (suicidal de-
pression), insomnia, anorexia, decreased libido, fatigue,
headache, muscle and joint pain and the desire to take
more steroids. Drugs that are targeted to relieve these
symptoms include antidepressants, non-steroidal anti-
inflammatory and clonidine.
Difficulties in overall therapeutic care
Comparisons between patients and control case series
are difficult because of the concealing of the practice,
but also due to various changes in consumption prac-
tices and doses employed [37]. However, male infertility
related to the abuse of AAS is underdiagnosed and yet it
is a potentially curable form. In the absence of spontan-
eous recovery of spermatogenesis following the cessation
of the AAS and after exclusion of other causes of infer-
tility, hormonal therapy should be initiated as a thera-
peutic alternative [25].
Conclusion
Anabolic steroids are able to increase strength and muscle
mass in some people when combined with a proper diet
and an intense training program. All anabolic steroids are
also androgenic. Anabolic steroids are marked with nu-
merous side effects, some of which are potentially fatal,
and some of which are permanent. However, most side ef-
fects are mild and reversible. Education alone is probably
not the miracle strategy inciting stopping the abuse of
anabolic steroids, but is an essential first step in the fight
against this problem. The common factor in the medical
literature available on the misuse of AAS is very het-
erogeneous. This limits objective comparisons between
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the different drugs and diets. The AAS abuse can disrupt
the health of the person at multiple levels. The impact on
male fertility is one of the least reported, but certainly one
that clinicians should know better. The infertility evalu-
ation of a AAS consumer should include a physical exam-
ination, a seminal analysis, a study of hormonal profile
and genetic analysis. Immediate cessation of the use of
AAS should be encouraged. A lack of awareness regarding
the negative long-term effects on fertility was the primary
factor related to regret of AAS use in men with anabolic-/
steroid-induced hypogonadism [38]. A particular attention
should be paid to dietary supplements called “without ste-
roids”. We are lead to the conclusion that the impact of
steroids on male fertility is not just a purely transitory
state. In short, the best policy is to strongly discourage the
use of steroids and, for consumers who persist in their
abuse, to offer them an appropriate ethics and clinical
uro-andrologic support.
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